Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given an average rating of “Buy” by the ten research firms that are covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $51.40.

Several research firms have recently commented on DYN. Piper Sandler restated an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research note on Monday. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Guggenheim increased their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Oppenheimer restated an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. increased their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 9th.

Insider Transactions at Dyne Therapeutics

In other news, CEO John Cox purchased 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Dyne Therapeutics news, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Susanna Gatti High sold 8,976 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the transaction, the chief operating officer now owns 131,636 shares of the company’s stock, valued at $4,529,594.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 132,947 shares of company stock worth $4,774,383. 20.77% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC increased its holdings in shares of Dyne Therapeutics by 255.1% in the 2nd quarter. Algert Global LLC now owns 97,370 shares of the company’s stock worth $3,436,000 after acquiring an additional 69,947 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Dyne Therapeutics by 96.2% in the second quarter. The Manufacturers Life Insurance Company now owns 126,244 shares of the company’s stock valued at $4,455,000 after purchasing an additional 61,902 shares during the period. AQR Capital Management LLC increased its stake in shares of Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after purchasing an additional 352 shares during the period. Affinity Asset Advisors LLC bought a new stake in shares of Dyne Therapeutics during the second quarter valued at approximately $3,529,000. Finally, First Light Asset Management LLC boosted its position in shares of Dyne Therapeutics by 261.0% during the second quarter. First Light Asset Management LLC now owns 382,433 shares of the company’s stock worth $13,496,000 after buying an additional 276,485 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $34.88 on Friday. Dyne Therapeutics has a 1 year low of $6.40 and a 1 year high of $47.45. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of -8.79 and a beta of 1.07. The stock’s 50-day moving average is $40.55 and its two-hundred day moving average is $33.78.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. As a group, research analysts predict that Dyne Therapeutics will post -2.96 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.